Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Forian Inc

Psychedelics-focused medicines company Mind Medicine Inc. (NASDAQ:MNMD), (NEO: MMED) announced Tuesday that it has teamed up with Forian Inc. (NASDAQ:FORA), a provider of evidence-based support for more comprehensive clinical and commercial decision-making. MindMed and Forian will collaborate to develop best practices for using real-world evidence ("RWE") information to help improve the health and lives of psychiatric patients.

MindMed Teams Up With Forian To Improve Real-World Evidence Data To Help Psychiatric Patients

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making. MindMed and Forian will collaborate to develop best practices for using real-world evidence ("RWE") information to help improve the health and lives of psychiatric patients.

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

Inclusion in the MSCI and FTSE Indices led to short-term gains that quickly evaporated.

Mind Medicine: Short-Term Catalysts Fall Flat

The acceptance of psychedelic treatments has been expedited over the past couple years, leaving companies like MindMed in great early positions to succeed. Normally, I would stay away from investing in biotech stocks; however, MindMed has the potential to revolutionize the healthcare industry, and I want to be a part of it.

MindMed: A Compelling Long-Term Buy In Biotech

NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute's ("C-Path's") Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science. C-Path ( www.c-path.org ) has multiple active consortia and programs that leverage knowledge sharing to spur innovation.

MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium

Mind Medicine (MindMed) Inc. (MNMD) CEO Robert Barrow on Q2 2021 Results - Earnings Call Transcript

Ready to explore an under-developed area of psychedelic medicine? If so, then consider a long position in low-priced MNMD stock.

Push the Boundaries of DMT Therapy with Mind Medicine

The psychedelics-focused medicines company MindMed (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ), announced its second-quarter financial results Friday with a net and comprehensive loss of $36 million, which compares to a loss of $14 million in the previous quarter. Net cash used in operating activities during the quarter amounted to $12 million, versus a total cash burn of $10 million in the quarter ended March 31.

MindMed Reports Q2 Earnings With Net Loss of $36M And Cash Balance Of $157M To Continue With Its Clinical Pipeline

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021. Q2 2021 Financial Highlights (in USD) Total assets as of June 30, 2021 were $194 million, including $157 million in cash Net Cash Used in Operating Activities of $12 million for the quarter ended June 30, 2021 Net and comprehensive loss of $36 million for the quarter ended June 30, 2021 Q2 2021 Business Highlights MindMed launched Project Angie, targeting the treatment of pain with psychedelics MindMed launched a collaboration with Nextage Therapeutics to explore applications of psychedelics in a brain targeting liposome delivery system MindMed and the Liechti Lab published the first pharmacogenetic data on LSD MindMed appointed Dr. Sarah Vinson to its Board of Directors MindMed appointed Drs.

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline

Atossa Genetics

Cinedigm

1847 GOEDEKER INC.

Globalstar

Cenntro Electric Group

Senseonics Holdings

SNDL Inc.

Uranium Energy

XpresSpa Group

These ten low-priced penny stocks have ample room to gain, making them each worthy of a small, speculative investment. The post 10 Penny Stocks to Buy to Create a $500 Portfolio appeared first on InvestorPlace.

10 Penny Stocks to Buy to Create a $500 Portfolio

While MNMD stock is controversial due to its underlying psychedelic therapies, the broader narrative is exceptionally compelling. The post No Matter How the Pandemic Rolls, Mind Medicine Will Prevail appeared first on InvestorPlace.

No Matter How the Pandemic Rolls, Mind Medicine Will Prevail

NEW YORK, Aug. 10, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D.

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and financially support the Digital Medicine Society's (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort to develop best practices and streamline the medical field's approaches to measuring health using digital technologies. DATAcc comprises leaders from across the US government, non-proﬁt, and private sectors, including the US Food and Drug Administration (FDA) , the US Department of Health and Human Services, healthcare systems, medical technology companies, patient advocates, biopharma, and policy organizations.

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

COMPASS Pathways

Green Thumb Industries Inc.

Neuronetics Inc

Here are seven stocks to buy if you're optimistic about the potential for alternative therapies to become mainstream treatments. The post 7 Stocks to Buy if You Think Alternative Therapies Are the Future appeared first on InvestorPlace.

7 Stocks to Buy if You Think Alternative Therapies Are the Future

Psychoactive brew ayahuasca is known for having a fast-onset antidepressant effect. With serotonergic psychedelics, such as ayahuasca, giving promising results in the quest for alternative treatments for depression and anxiety, many companies are turning their focus to developing psychedelic-inspired therapies.

MindMed Leverages Ayahuasca's Ingredient DMT In Psychedelic-Inspired Therapies, Launches Trials With 30 Subjects

NEW YORK, July 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT, a naturally occurring psychedelic substance and an active ingredient in ayahuasca. The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients.

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business. The post Mind Medicine Has More Obstacles Than Opportunities appeared first on InvestorPlace.

Mind Medicine Has More Obstacles Than Opportunities

NEW YORK, July 12, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Executive Officer, Robert Barrow, will be leading a roundtable discussion at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit. The event is set to take place on July 13th, 2021 from 4:15-5:00pm ET.

MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit

Annovis Bio

Brooklyn ImmunoTherapeutics

Citius Pharmaceuticals

Jazz Pharmaceuticals

Cassava Sciences Inc

SpringWorks Therapeutics Inc

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Companies to Invest In for July

MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about. The post MindMed Stock Is Overvalued and Too Risky to Own appeared first on InvestorPlace.

MindMed Stock Is Overvalued and Too Risky to Own

NEW YORK, July 8, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources.  MindMed plans to use Datavant's linking technology across various stages of the drug lifecycle including discovery, clinical development, and commercialization.

MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants.

The MindMed Psychedelic Revolution Will Take Years to Come to Fruition

Ameri Holdings

Institutional analysts are taking a liking to the industry of medicinal psychedelics. This week, investment bank Maxim Group initiated coverage of companies in the psychedelics space, giving a bullish Buy rating to all 10.

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More

These companies developing hallucinogens have more than meets the eye.

3 Top Psychedelic Stocks to Buy Now

MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments. The post Get a Dose of Innovative Science With Mind Medicine appeared first on InvestorPlace.

News for Mind Medicine MindMed Stock (MNMD)